| Authors: |
Uray IP; Breast Cancer Center and Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas 77030 and Ligand Pharmaceuticals Ltd., San Diego, California 92121; Breast Cancer Center and Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas 77030 and Ligand Pharmaceuticals Ltd., San Diego, California 92121., Shen Q; Breast Cancer Center and Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas 77030 and Ligand Pharmaceuticals Ltd., San Diego, California 92121; Breast Cancer Center and Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas 77030 and Ligand Pharmaceuticals Ltd., San Diego, California 92121., Seo HS; Breast Cancer Center and Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas 77030 and Ligand Pharmaceuticals Ltd., San Diego, California 92121., Kim H; Breast Cancer Center and Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas 77030 and Ligand Pharmaceuticals Ltd., San Diego, California 92121., Lamph WW; Breast Cancer Center and Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas 77030 and Ligand Pharmaceuticals Ltd., San Diego, California 92121., Bissonnette RP; Breast Cancer Center and Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas 77030 and Ligand Pharmaceuticals Ltd., San Diego, California 92121., Brown PH; Breast Cancer Center and Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas 77030 and Ligand Pharmaceuticals Ltd., San Diego, California 92121; Breast Cancer Center and Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas 77030 and Ligand Pharmaceuticals Ltd., San Diego, California 92121. Electronic address: pbrown@breastcenter.tmc.edu. |